APOE Gene Linked to Up to 93% of Alzheimer’s Cases – New Research

A single gene, APOE, may be a far more significant driver of Alzheimer’s disease than previously understood, potentially accounting for 72% to 93% of cases depending on how the disease is measured. A new analysis, published in npj Dementia, suggests this common gene deserves increased attention as a target for future treatments and preventative strategies, even as lifestyle and environmental factors continue to play a role.

For decades, researchers have understood that genetic factors influence Alzheimer’s risk, but the extent to which a single gene could be so broadly involved is striking. This finding doesn’t mean Alzheimer’s is inevitable for those with certain APOE variants, but it does highlight a crucial area for further investigation.

The APOE Gene: More Than Just ε4

The APOE gene comes in three common forms, called alleles: ε2, ε3, and ε4. Everyone inherits two copies of this gene – one from each parent – resulting in six possible combinations. While the ε4 allele has long been recognized as increasing Alzheimer’s risk, and ε2 appearing to offer some protection, the ε3 allele has often been considered relatively neutral. This new research challenges that assumption.

Researchers at University College London (UCL) found that considering both the ε3 and ε4 alleles together reveals a much larger impact of the APOE gene on Alzheimer’s disease than previously estimated. Lead author Dr. Dylan Williams explained that the disease risk has likely been underestimated because of the focus on ε4 while underappreciating the contribution of the more common ε3 allele. The study suggests that intervening on the APOE gene, or the biological pathways it influences, could potentially prevent a majority of Alzheimer’s cases.

How the Study Reached Its Conclusions

The UCL team arrived at these estimates by combining data from four large datasets, each using different methods to track Alzheimer’s and dementia. Two datasets – the UK Biobank and FinnGen – included health records of over 460,000 people aged 60 and older. The A4 Study used brain scans (amyloid PET scans) to measure amyloid buildup before symptoms appeared in over 4,400 participants. Finally, data from the Alzheimer’s Disease Genetics Consortium included brain tissue analysis from individuals with and without Alzheimer’s.

This multi-faceted approach is significant because Alzheimer’s can be defined and diagnosed in various ways. By combining these different methods, the researchers aimed to create a more comprehensive picture of APOE’s role. The inclusion of individuals with two copies of the ε2 allele – considered the lowest risk group – also allowed for clearer estimates of the risk associated with the more common ε3 and ε4 variants.

Understanding the Numbers: Risk and Attribution

The study estimates that 72% to 93% of Alzheimer’s cases may be linked to the ε3 and ε4 variants of APOE. For dementia the gene may account for around 45% of cases. These figures are higher than previous estimates because they consider the combined effects of both ε3 and ε4. It’s important to note that these are estimates, and variations between the datasets reflect differences in how Alzheimer’s and dementia were defined and measured within each study.

These findings don’t suggest a simple cause-and-effect relationship. Even among individuals with two copies of the ε4 allele – the highest risk group – the lifetime risk of developing Alzheimer’s remains below 70%. This highlights the complex interplay between genetics and other contributing factors, such as lifestyle and environmental influences. Modifiable risk factors like social isolation, high cholesterol, and smoking can also play a significant role.

What Does This Mean for Treatment and Prevention?

The researchers emphasize that APOE should be a central focus in future research on Alzheimer’s disease mechanisms and drug development. Dr. Williams points to advances in gene editing and gene therapy as potential avenues for directly targeting the genetic risk factor. Understanding the molecular pathways between the APOE gene and the disease could lead to the development of more conventional drugs.

However, it’s crucial to remember that genetic risk is not destiny. As Dr. Williams explains, most people with genetic risk factors won’t develop dementia during their lifetime due to the complex interactions of various genetic and environmental factors. Understanding how these factors modify the risk inherited from APOE genes is a key area for ongoing research.

The Role of APOE Variants: A Closer Look

Previous research suggests that the ε4 variant may increase dementia risk by reducing the effectiveness of the protein it produces in clearing amyloid-beta, a sticky protein that forms plaques in the brain. It may also interfere with fat and energy apply in brain cells and promote inflammation. While these processes are suspected, further research is needed to confirm them and to understand why the ε3 variant also carries higher risk than ε2. ApoE’s role in Alzheimer’s is complex and involves multiple pathways.

What’s Next in Alzheimer’s Research?

Alzheimer’s Research UK’s Director of Research, Dr. Sheona Scales, notes that this study reinforces the need for further research into APOE to develop future prevention and treatment strategies. While APOE is linked to Alzheimer’s, few treatments currently in clinical trials directly target this gene. This highlights a potential gap in research and development efforts.

The focus now will likely be on unraveling the specific mechanisms by which APOE variants influence Alzheimer’s risk and exploring potential therapeutic interventions. This includes investigating how to reduce the harmful effects of the ε3 and ε4 alleles and potentially enhance the protective effects of the ε2 allele. Continued research into modifiable risk factors, alongside genetic investigations, will be crucial for developing a comprehensive approach to preventing and treating Alzheimer’s disease.